MedTrace Logo

Routine Application of Ostenil® in Patients with Gonarthrosis

NCT03734315 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2024-10-09

No results posted yet for this study

Summary

PMCF study to observe the routine application of Ostenil® in the treatment of pain and restricted mobility in degenerative and traumatic changes of the knee joint.

Conditions

  • Gonarthrosis

Interventions

DEVICE

Ostenil®

Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.

Sponsors & Collaborators

  • TRB Chemedica AG

    lead INDUSTRY

Principal Investigators

  • Michael Krüger-Franke, Dr. med. · MVZ am Nordbad

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-08
Primary Completion
2023-01-12
Completion
2023-01-12

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03734315 on ClinicalTrials.gov